Literature DB >> 15330643

Synthesis of BILN 2061, an HCV NS3 protease inhibitor with proven antiviral effect in humans.

Anne-Marie Faucher1, Murray D Bailey, Pierre L Beaulieu, Christian Brochu, Jean-Simon Duceppe, Jean-Marie Ferland, Elise Ghiro, Vida Gorys, Ted Halmos, Stephen H Kawai, Martin Poirier, Bruno Simoneau, Youla S Tsantrizos, Montse Llinàs-Brunet.   

Abstract

The synthesis of BILN 2061, an NS3 protease inhibitor with proven antiviral effect in humans, was accomplished in a convergent manner from four building blocks. The procedure described here was suitable for the preparation of multigram quantities of BILN 2061 for preclinical pharmacological evaluation. Copyright 2004 American Chemical Society

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15330643     DOI： 10.1021/ol0489907

Source DB:  PubMed          Journal:  Org Lett        ISSN： 1523-7052            Impact factor:   6.005


  8 in total

1.  Policresulen, a novel NS2B/NS3 protease inhibitor, effectively inhibits the replication of DENV2 virus in BHK-21 cells.

Authors:  Deng-wei Wu; Fei Mao; Yan Ye; Jian Li; Chuan-lian Xu; Xiao-min Luo; Jing Chen; Xu Shen
Journal:  Acta Pharmacol Sin       Date:  2015-08-17       Impact factor: 6.150

2.  VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCv replicon cells.

Authors:  Kai Lin; Robert B Perni; Ann D Kwong; Chao Lin
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

3.  Utility of alkylaminoquinolinyl methanols as new antimalarial drugs.

Authors:  G S Dow; T N Heady; A K Bhattacharjee; D Caridha; L Gerena; M Gettayacamin; C A Lanteri; N Obaldia; N Roncal; T Shearer; P L Smith; A Tungtaeng; L Wolf; M Cabezas; D Yourick; K S Smith
Journal:  Antimicrob Agents Chemother       Date:  2006-09-11       Impact factor: 5.191

4.  Stereoselective synthesis of spirooxindole amides through nitrile hydrozirconation.

Authors:  Chunliang Lu; Qing Xiao; Paul E Floreancig
Journal:  Org Lett       Date:  2010-10-20       Impact factor: 6.005

Review 5.  New therapeutic approaches to hepatitis C virus.

Authors:  Naoya Sakamoto; Mamoru Watanabe
Journal:  J Gastroenterol       Date:  2009-05-21       Impact factor: 7.527

Review 6.  Macrocyclic drugs and synthetic methodologies toward macrocycles.

Authors:  Xufen Yu; Dianqing Sun
Journal:  Molecules       Date:  2013-05-24       Impact factor: 4.411

7.  Substituted imidazopyridines as potent inhibitors of HCV replication.

Authors:  Inge Vliegen; Jan Paeshuyse; Tine De Burghgraeve; Laura S Lehman; Matthew Paulson; I-Hung Shih; Eric Mabery; Nina Boddeker; Erik De Clercq; Hans Reiser; David Oare; William A Lee; Weidong Zhong; Steven Bondy; Gerhard Pürstinger; Johan Neyts
Journal:  J Hepatol       Date:  2009-02-26       Impact factor: 25.083

8.  Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors.

Authors:  Lotte Coelmont; Suzanne Kaptein; Jan Paeshuyse; Inge Vliegen; Jean-Maurice Dumont; Grégoire Vuagniaux; Johan Neyts
Journal:  Antimicrob Agents Chemother       Date:  2008-12-22       Impact factor: 5.191
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.